1. Home
  2. WFC vs NVO Comparison

WFC vs NVO Comparison

Compare WFC & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Wells Fargo & Company

WFC

Wells Fargo & Company

HOLD

Current Price

$87.69

Market Cap

224.7B

Sector

Finance

ML Signal

HOLD

Logo Novo Nordisk A/S

NVO

Novo Nordisk A/S

HOLD

Current Price

$51.34

Market Cap

218.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WFC
NVO
Founded
1852
1923
Country
United States
Denmark
Employees
200999
69500
Industry
Major Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
224.7B
218.9B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
WFC
NVO
Price
$87.69
$51.34
Analyst Decision
Buy
Hold
Analyst Count
18
11
Target Price
$96.59
$51.00
AVG Volume (30 Days)
10.3M
9.1M
Earning Date
04-14-2026
05-06-2026
Dividend Yield
2.21%
3.19%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$11.08
N/A
Revenue Next Year
$4.76
$3.70
P/E Ratio
$14.15
$13.60
Revenue Growth
N/A
N/A
52 Week Low
$72.78
$35.12
52 Week High
$97.76
$71.80

Technical Indicators

Market Signals
Indicator
WFC
NVO
Relative Strength Index (RSI) 62.14 70.43
Support Level $80.15 $50.55
Resistance Level $95.47 $53.63
Average True Range (ATR) 2.00 1.04
MACD 0.01 0.12
Stochastic Oscillator 85.42 93.72

Price Performance

Historical Comparison
WFC
NVO

About WFC Wells Fargo & Company

Wells Fargo is a premier, North American-focused banking titan that commands a $2.2 trillion balance sheet and the third-highest deposit market share in the United States. The bank uses a dense, expansive network of 4,093 branches to champion retail consumers and the middle market, where the firm has built a particularly strong reputation. Following the removal of its federal asset cap in 2025, the firm is set to deploy its legacy excess liquidity to expand each of its four segments: consumer & business lending, commercial banking, corporate & investment banking, and wealth & investment management.

About NVO Novo Nordisk A/S

With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Share on Social Networks: